Takeda Pharmaceutical Company Limited

Takeda reported Q1 FY26 revenue of JPY 1.22 trillion, up 10.2% year over year on an actual FX basis and down 0.5% at constant exchange rates. Core operating profit was JPY 358.9 billion, up 11.5% actual FX and down 0.5% CER; reported operating profit was JPY 201.4 billion. Core EPS was JPY 154, down 11.8% CER, and reported EPS was JPY 72. Operating cash flow was lower than the prior year due to working capital changes tied to trade receivables factoring, and adjusted free cash flow included a USD 200 million payment to Protagonist after Takeda opted out of the rusfertide co-promotion agreement. For FY26, management said full-year guidance is unchanged, including JPY 650 billion to JPY 750 billion in free cash flow and a gross margin target of 65%.

Julie Kim framed the quarter as a steady start to FY26 and said Takeda is making progress on its 2-Horizon strategy, with Horizon One focused on transformation, launch readiness, and protecting the core portfolio. She repeatedly pointed to ORZEYFUL, rusfertide and zasocitinib as the foundation for future growth and said Takeda is preparing for those launches through payer work, field teams, patient support and commercial infrastructure. Her tone was confident and forward-looking, but disciplined, stressing value recognition, fast access, and structural margin expansion over time.

Milano Furuta said Q1 results were on track to full-year guidance, with revenue of JPY 1.22 trillion, core operating profit of JPY 358.9 billion, core EPS of JPY 154, and reported EPS of JPY 72. He noted that core revenue declined 0.5% CER because gains from core in-line brands and new launches offset LOE and mature product pressure, while gross profit benefited from favorable FX in cost of goods and a small one-time divestiture-related milestone. He also said the transformation program is still early in its savings ramp because many initiatives were implemented near quarter-end, and reiterated the company’s focus on strong free cash flow, margin protection, and disciplined investment.

Analysts focused heavily on gross margin, launch strategy, and the mechanics of upcoming catalysts. Management said the Q1 gross margin benefit was driven mostly by PDT and favorable FX, while the divestiture-related technology transfer milestone was small and “almost negligible” on a full-year basis; they kept the 65% full-year gross margin outlook unchanged. On ORZEYFUL, Julie said Takeda expects it to be used as monotherapy, with early growth coming from already diagnosed NT1 patients on therapy and later growth from better diagnosis, while pricing will aim to balance value recognition and fast access. Questions also covered TAK-360’s adaptive design, zasocitinib’s UC/Crohn’s data timing, ENTYVIO demand and biosimilar risk, and rusfertide pricing; Takeda said TAK-360 data should come this year, zasocitinib IBD data are expected by fiscal year-end, ENTYVIO’s U.S. biosimilar timing remains roughly 3 to 5 years in litigation, and rusfertide pricing will likewise seek value recognition plus access.